Rapid Oligonucleotides QC with Automated High Resolution ESI-LCMS and BioPharma Compass
Applications | 2020 | BrukerInstrumentation
Oligonucleotides, short DNA or RNA sequences, are indispensable tools in genetic testing, molecular diagnostics, forensics and drug development. Ensuring their correct synthesis and purity is critical, as by-products or modifications can compromise downstream applications. High-resolution mass spectrometry (MS), coupled with automated workflows, provides robust quality control (QC) to meet rigorous accuracy and throughput demands in both research and pharmaceutical environments.
This study presents a fully automated UPLC-MS approach for rapid QC of synthetic oligonucleotides using BioPharma Compass software. Key objectives include demonstration of seamless integration from sample submission to report generation, evaluation of mass accuracy and sensitivity for by-product detection, and assessment of workflow compliance with regulatory requirements (21 CFR Part 11).
The workflow combines high-performance liquid chromatography and quadrupole time-of-flight MS under a single control platform. The UPLC separation employs a BEH C4 column (1.7 µm, 1 × 100 mm) at 80 °C with a flow rate of 500 µL/min. Mobile phases are:
One microgram of each oligonucleotide sample in water is injected. Detection is performed on a maXis II ETD UHR QTOF in negative ion mode with these source parameters:
Data acquisition, processing and reporting are orchestrated through BioPharma Compass. Sample batches can be defined manually or imported via LIMS worklists. Acquired data are automatically transferred to a secure processing server to maintain integrity and compliance. Spectral deconvolution uses a Maximum Entropy algorithm to yield neutral average molecular weights.
The integrated interface provides result tables, chromatogram and spectrum views, and similarity scoring for rapid QC assessment. Key findings include:
The workflow achieves high throughput with minimal user intervention, while maintaining data security and audit trails for regulatory compliance.
This automated UPLC-MS QC platform delivers:
By reducing manual processing steps and standardizing data analysis, laboratories can improve throughput and reproducibility in oligonucleotide QC.
Advancements may include integration of AI-driven spectral interpretation, expansion to MALDI-MS platforms for complementary analyses, and implementation of in-line QC within synthesis instruments. Further development of cloud-based data management could enhance collaborative research and real-time monitoring of production processes.
The presented automated UPLC-MS workflow, managed by BioPharma Compass, offers a comprehensive solution for high-resolution oligonucleotide QC. It streamlines sample handling, ensures robust mass accuracy and impurity detection, and provides clear, compliance-ready reporting. This approach addresses the growing demand for reliable and efficient oligonucleotide analysis in both academic and industrial settings.
LC/TOF, LC/HRMS, LC/MS, LC/MS/MS
IndustriesClinical Research
ManufacturerBruker
Summary
Significance of the Topic
Oligonucleotides, short DNA or RNA sequences, are indispensable tools in genetic testing, molecular diagnostics, forensics and drug development. Ensuring their correct synthesis and purity is critical, as by-products or modifications can compromise downstream applications. High-resolution mass spectrometry (MS), coupled with automated workflows, provides robust quality control (QC) to meet rigorous accuracy and throughput demands in both research and pharmaceutical environments.
Objectives and Study Overview
This study presents a fully automated UPLC-MS approach for rapid QC of synthetic oligonucleotides using BioPharma Compass software. Key objectives include demonstration of seamless integration from sample submission to report generation, evaluation of mass accuracy and sensitivity for by-product detection, and assessment of workflow compliance with regulatory requirements (21 CFR Part 11).
Methodology and Instrumentation
The workflow combines high-performance liquid chromatography and quadrupole time-of-flight MS under a single control platform. The UPLC separation employs a BEH C4 column (1.7 µm, 1 × 100 mm) at 80 °C with a flow rate of 500 µL/min. Mobile phases are:
- Solvent A: 1% HFIP, 0.1% hexylamine in water
- Solvent B: 50% acetonitrile, 50% methanol
One microgram of each oligonucleotide sample in water is injected. Detection is performed on a maXis II ETD UHR QTOF in negative ion mode with these source parameters:
- Mass range: 300–3000 m/z
- Capillary voltage: 3500 V
- Dry gas: 1.8 L/min at 220 °C
- Nebulizer pressure: 10 bar
Data acquisition, processing and reporting are orchestrated through BioPharma Compass. Sample batches can be defined manually or imported via LIMS worklists. Acquired data are automatically transferred to a secure processing server to maintain integrity and compliance. Spectral deconvolution uses a Maximum Entropy algorithm to yield neutral average molecular weights.
Used Instrumentation
- Bruker Elute UPLC system with BEH C4 column (1 × 100 mm, 1.7 µm)
- Bruker maXis II ETD UHR QTOF mass spectrometer
- BioPharma Compass software for automated acquisition, processing and reporting
Main Results and Discussion
The integrated interface provides result tables, chromatogram and spectrum views, and similarity scoring for rapid QC assessment. Key findings include:
- Mass accuracy within 0.6 ppm across multiple oligonucleotide sequences
- Reliable detection of truncated or modified by-products at low abundance
- Automated pass/fail decisions based on multi-attribute screening (base peak matching, mass accuracy, intensity coverage)
- Color-coded reports summarizing chromatographic and spectral data
The workflow achieves high throughput with minimal user intervention, while maintaining data security and audit trails for regulatory compliance.
Benefits and Practical Applications of the Method
This automated UPLC-MS QC platform delivers:
- Rapid turnaround times for oligonucleotide batch verification
- High sensitivity and accuracy for impurity profiling
- Seamless integration with LIMS and compliance with 21 CFR Part 11
- User-friendly reports facilitating decision-making in manufacturing and research laboratories
By reducing manual processing steps and standardizing data analysis, laboratories can improve throughput and reproducibility in oligonucleotide QC.
Future Trends and Opportunities
Advancements may include integration of AI-driven spectral interpretation, expansion to MALDI-MS platforms for complementary analyses, and implementation of in-line QC within synthesis instruments. Further development of cloud-based data management could enhance collaborative research and real-time monitoring of production processes.
Conclusion
The presented automated UPLC-MS workflow, managed by BioPharma Compass, offers a comprehensive solution for high-resolution oligonucleotide QC. It streamlines sample handling, ensures robust mass accuracy and impurity detection, and provides clear, compliance-ready reporting. This approach addresses the growing demand for reliable and efficient oligonucleotide analysis in both academic and industrial settings.
References
- Tech Note: Automated High-Throughput Oligo QC: From Automated Sample Preparation to MALDI Spectra Assessment, Bruker Daltonics, TN-50, July 2020.
- Flash Note: The Complete Solution: Oligonucleotide, Bruker Daltonics, FN-007, March 2019.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Automated High-Throughput Oligo QC: From Automated Sample Preparation to MALDI Spectra Assessment
2020|Bruker|Applications
Automated High-Throughput Oligo QC: From Automated Sample Preparation to MALDI Spectra Assessment Synthetic oligonucleotides find a variety of applications in molecular biology. Primers for instance are used for DNA sequencing and amplification. Mass spectrometry is a well-established technology for quality…
Key words
maldi, maldicta, ctagac, gacprimers, primersanchorchip, anchorchipspectra, spectramass, masscgg, cggpreparation, preparationoligo, oligoagg, agggct, gctcag, cagtaa, taabruker
Automated Analysis of Protein Sequence Variants by LC-MS Under the Control of BioPharma Compass
2012|Waters|Applications
Application Note # LCMS-78 Automated Analysis of Protein Sequence Variants by LC-MS Under the Control of BioPharma Compass Abstract Here we describe an automated UPLC-MS based method for the analysis and quality confirmation of the intact mass for protein sequence…
Key words
compass, compassalbumin, albuminbiopharma, biopharmavariants, variantsintact, intactprotein, proteinbruker, brukertraceably, traceablymass, masstable, tableacceptance, acceptanceprocessed, processedmicrotof, microtofhalf, halfautomated
Routine analysis of drug to antibody ratio and drug distribution with maXis II
2020|Bruker|Applications
Routine analysis of drug to antibody ratio and drug distribution with maXis II Antibody drug conjugates (ADC) are small molecule conjugated mAbs. These are rapidly emerging complex biological molecules in the biopharma space. Abstract Characterization of ADC’s includes intact mass…
Key words
dar, daradc, adcmaxis, maxisbruker, brukerdrug, drugantibody, antibodylinker, linkerconjugation, conjugationaverage, averagemab, mabglycoforms, glycoformsdenaturing, denaturingpotency, potencyconjugated, conjugatedlysine
Fully automated glycoform profiling and sequence validation of the NIST reference antibody
2017|Bruker|Applications
Fully automated glycoform profiling and sequence validation of the NIST reference antibody Abstract Two key elements assessed during the analysis of mAb biotherapeutics are the glycosylation profile and the primary sequence. Using the NIST antibody as a model, three complementary…
Key words
antibody, antibodybruker, brukermodifications, modificationssubunit, subunitfragment, fragmentisotopic, isotopicnist, nistintact, intactglycoforms, glycoformssequence, sequenceaglycan, aglycanpyroglutamylation, pyroglutamylationbiopharmaceutical, biopharmaceuticalbiopharma, biopharmamass